5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The IGF-1 dependent feedback activation of AKT
    Meeting Abstract

    Oreilly, K. E.; She, Q. B.; Solit, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Baselga, J.; Rosen, N.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • V599E B-Raf as the next HSP90 client protein: A novel strategy for selective inhibition of mutated B-Raf
    Meeting Abstract

    Grbovic, O. M.; Basso, A.; Solit, D.; Rosen, N.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Treatment of melanoma patients with 17AAG results in downregulation of the MAPK pathway in the melanoma tumors
    Meeting Abstract

    Friedlander, P.; Solit, D.; Osman, I.; Polsky, D.; Elamparo, R.; Rosen, N.; Chapman, P. B.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Fludelone, an optimized epothilone for ovarian cancer treatment
    Meeting Abstract

    Dorn, D. C.; Cho, Y. S.; Procissi, D.; Liedtke, M.; Zhang, K.; Ponomarev, V.; Koutcher, J. A.; Danishefsky, S. J.; Moore, M. A. S.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • The clinical significance of a PSA nadir > 0.2 to patients with a rising post-operative or post-radiation PSA treated with androgen deprivation
    Meeting Abstract

    Stewart, A. J.; Scher, H.; Chen, M. H.; McLeod, D.; Carroll, P.; Moul, J.; D'Amico, A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • FLT PET as a non-invasive marker of response to MEK inhibition
    Meeting Abstract

    Solit, D. B.; Santos, E.; Pratilas, C.; Moroz, M.; Blasberg, R.; Sebolt-Leopold, J.; Larson, S. M.; Rosen, N.
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin)
    Meeting Abstract

    Solit, D. B.; Egorin, M.; Kopil, C.; Delacruz, A.; Shaffer, D.; Slovin, S.; Morris, M.; Kelly, W. K.; Rosen, N.; Scher, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
    Meeting Abstract

    Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • The men's cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state
    Meeting Abstract

    Slovin, S. F.; Carducci, M. A.; Beekman, K. W.; Pili, R.; Eicher, C.; Kelly, W. K.; Morris, M. J.; Shaffer, D.; Eisenberger, M.; Scher, H. I.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • 2-MPPA, a selective inhibitor of PSMA, delays prostate cancer growth and attenuates taxol-induced neuropathy in mice
    Meeting Abstract

    She, Y.; Tang, Z.; Lapidus, R. G.; Wozniak, K. M.; Scher, H. I.; Slusher, B. S.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save